Poly(oxyethylene) sorbitan trioleate
CAS 9005-70-3
Poly(oxyethylene) sorbitan trioleate (CAS 9005-70-3) is a pharmaceutical compound with 0 bioactivity targets and 100 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Cross-Reference to Chemicals
Same-CAS substance identity is available in the industrial chemicals vertical.
Poly(oxyethylene) sorbitan trioleate is linked to DTXSID4049743 in DSSTox identifiers.
View industrial chemical data →Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Poly(oxyethylene) sorbitan trioleate used for in pharmaceutical contexts?
Poly(oxyethylene) sorbitan trioleate (CAS 9005-70-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Poly(oxyethylene) sorbitan trioleate?
Poly(oxyethylene) sorbitan trioleate has 100 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Balance disorder, Bladder disorder, Blood calcium decreased, Cognitive disorder, Constipation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Poly(oxyethylene) sorbitan trioleate also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for PEG-30 Sorbitan Tetraoleate with EU status "permitted".
What clinical phase is Poly(oxyethylene) sorbitan trioleate in?
No phase 1-4 clinical development badge is rendered for Poly(oxyethylene) sorbitan trioleate because the matched compound identifier rows do not contain a max-phase value.